FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk

 
• By The Pink Sheet

The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet